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Abstract
Antibiotic use is considered among the most severe causes of disturbance to children’s
developing intestinal microbiota, and frequently causes adverse gastrointestinal effects
ranging frommild and transient diarrhoea to life-threatening infections. Probiotics are com-
monly advocated to help in preventing antibiotic-associated gastrointestinal symptoms.
However, it is currently unknown whether probiotics alleviate the antibiotic-associated
changes in children’s microbiota. Furthermore, it is not known how long-term probiotic con-
sumption influences the developing microbiota of children. We analysed the influence of
long-term Lactobacillus rhamnosusGG intake on preschool children’s antibiotic use, and
antibiotic-associated gastrointestinal complaints in a double blind, randomized placebo-con-
trolled trial with 231 children aged 2–7. In addition, we analysed the effect of L. rhanmosus
GG on the intestinal microbiota in a subset of 88 children. The results show that long-term L.
rhamnosusGG supplementation has an influence on the composition of the intestinal micro-
biota in children, causing an increase in the abundance of Prevotella, Lactococcus, and
Ruminococcus, and a decrease in Escherichia. The treatment appeared to prevent some of
the changes in the microbiota associated with penicillin use, but not those associated with
macrolide use. The treatment, however, did reduce the frequency of gastrointestinal com-
plaints after a macrolide course. Finally, the treatment appeared to prevent certain bacterial
infections for up to 3 years after the trial, as indicated by reduced antibiotic use.
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Introduction
Antibiotics account for the majority of prescription medication used by children in western
countries [1] and relatively frequently cause diarrhoea in this demographic [2], which indicates
that antibiotic use influences intestinal health. Hence, antibiotic use has been implicated as the
strongest and the most common cause of disturbance to the intestinal microbiota [3]. It has
been suggested that due to their impact on the commensal microbiota and thereby reduced col-
onization resistance, antibiotics predispose the patient to life-threatening intestinal infections
with pathogens such as Clostridium difficile [4]. Several studies have shown changes in the
intestinal microbiota in response to oral antibiotic treatments in adult humans [5–8] and in
animals [9–11]: the immediate effect is usually a reduction in total bacterial abundance and
diversity, after which antibiotic-resistant species or opportunistic species with fast intrinsic
growth rates repopulate the vacated niches, altering the ecological balance in the intestine, the
metabolic functions of the microbiota and the host-microbe interactions and host immune
function [11, 12]. Bile acid and steroid metabolism has been shown to decrease, and the metab-
olism of sugars and starch to increase after an antibiotic course [11].
Animal experiments have demonstrated that early-life antibiotic use disrupts the micro-
biota and consequently immune function and metabolism, predisposing to the development
of obesity [13,14] and allergic disease [15,16]. Recent studies have indicated that the growth-
promoting and obesogenic effects of antibiotic use also are manifested in humans [17–20].
The association between antibiotic use and the development of asthma in children has been
established, although causality is yet to be confirmed [21]. Due to these potentially detrimen-
tal changes, there is a need to mitigate the damage antibiotics cause on the symbiotic micro-
biota. One commonly advocated option is the use of specific microorganisms that are
marketed as probiotics.
Probiotics have been recently redefined as live microorganisms that when administered in
adequate amounts confer a health benefit on the host [22]. Lactic acid bacteria and bifidobac-
teria are among the most commonly used probiotics. The evidence for their efficacy varies
between strains, aimed health outcomes, and study cohorts [23,24]. Lactobacillus rhamnosus
GG is one of the best studied probiotics [25] and meta-analyses have shown this bacterium to
be effective in the treatment of many gastrointestinal illnesses in children: it reduces gastroin-
testinal pain [26], Clostridium difficile -associated diarrhoea [27], hospital-acquired diar-
rhoea [28], antibiotic-associated diarrhoea [29], and the duration of infectious diarrhoea
[30]. Short-term probiotic use has not been found to result in large changes in faecal micro-
biota composition of adults [31,32]. This suggests that the mode of action may be related to
altered microbial metabolism or direct interaction with the host [24]. L. rhamnosus GG pro-
duces pili decorated with the mucus-binding protein SpaC [33]. The pili have been impli-
cated in various signalling effects, including those with the immune system [24,34]. There is
some indication that probiotics may alleviate the antibiotic-induced alterations in the com-
position of the intestinal microbiota [35,36].
The long-term effects of continuous probiotic use on the developing intestinal microbiota of
children, and its potential to protect from antibiotic-associated changes in the microbiota, are
not well documented. L. rhamnosus GG is available in various food products and pharmaceuti-
cal formulations, making the continuous consumption of this strain very common. In this
study we address the effect of long-term consumption of L. rhamnosus GG on the health out-
come and microbiota of a cohort of preschool children by utilizing antibiotic purchase records
and culture-independent microarray analysis of the faecal microbiota.
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Materials And Methods
Participants and study design
The study is based on a double-blind placebo-controlled trial, conducted during the winter
2009–2010, investigating the effect of L. rhamnosus GG supplementation on the occurrence of
viral respiratory infections in children aged 2–6 years [37]. The study was approved by the Eth-
ics Committee of Joint Authority of Kainuu Region and registered to http://clinicaltrials.gov
with the identifier NCT01014676. The parents provided written informed consent. The partici-
pants were randomly assigned into probiotic and placebo treatment groups, both receiving
three ad libitum doses of milk daily, on average 400 ml per day. The probiotic treatment group
received milk containing L. rhamnosus GG (L. rhamnosus GG; approximately 106 cfu/ml,
Valio Gefilus milk 1% fat), and the placebo group received similar milk (Valio 1%) without the
probiotic. The participants were guided not to use probiotic products during the intervention
and three weeks prior to the intervention. The intervention continued for seven months (Octo-
ber 2009–April 2010). All participants attended a health check and were asked to provide a fae-
cal sample at the beginning and end of the intervention period. Compliance with the milk
intake in both groups was monitored by the day care staff and parents, who recorded the daily
intake. Moreover, parents kept daily symptom diaries throughout the intervention, marking-
down various gastrointestinal and respiratory complaints. For the current study, the frequency
of gastrointestinal complaints (pain, bloating, diarrhoea, constipation, flatulence) per day was
calculated before, during and after antibiotic treatment for the children who used antibiotics
during the intervention to assess the ability of the probiotic to reduce antibiotic-associated gas-
trointestinal complaints.
Originally a total of 501 children completed the study. Exclusion criteria in the original
study were milk allergy, lactose intolerance, congenital heart disease requiring regular medica-
tion, malignant diseases, cytostatic treatment, use of biological rheumatic medication, continu-
ous microbial medication, regular use of oral corticosteroids, diabetes and simultaneous
participation in other clinical trials. Written informed consent (by the parents) to access the
antibiotic purchase records was provided by 231 children. The national individual-based drug
purchase registry of the Finnish Social Insurance Institute was utilized to obtain information
on antibiotic purchases during the intervention and for three years after the intervention (until
the end of 2012). The collection of antibiotic purchase records was approved by the ethical
boards of the Helsinki and Uusimaa Hospital Region, and the Social Insurance Institute. We
categorized the antibiotics into penicillins, (phenoxymethylpenicillin, amoxicillin, amoxicillin
with clavulanic acid), 1st generation cephalosporins, macrolides (azithromycin and clarithro-
mycin), and sulphonamide-trimethoprim. Antibiotics in Finland are only available by pre-
scription by a medical doctor, but prescriptions can be made without a positive bacterial
culture. Therefore, the antibiotic purchases reflect bacterial infections, but the correlation may
not be perfect. It is possible that viral infection are sometimes incorrectly diagnosed as bacterial
and treated with antibiotics.
For the microbiota analysis, 88 children were selected based on the following criteria: avail-
ability of both faecal samples; adequate DNA yield from both faecal samples; and compliance
with the probiotic/placebo treatment based on PCR-detection (or absence) of L. rhamnosus
GG in the samples (Fig 1). The PCR-test was conducted on all samples, including the control
samples to ensure that had not consumed products containing LGG. In the original study, the
children were randomized into the two treatment groups; however, for this study a sub-cohort
was selected and therefore we considered the possibility that the children were non-randomly
distributed between the groups in this sub-cohort. However, we found no significant differ-
ences between the children included in the microbiota analyses and those not included
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(Table 1). Furthermore, we found no significant baseline differences in age, duration of breast-
feeding, weight, height, lifetime antibiotic use, or the number of cases with asthma or allergies
between the placebo and LGG group among the children whose microbiota was analysed
(Tables 1 and 2). Nevertheless, we used each child’s own baseline microbiota sample as a covar-
iate in the models, to control for any potentially unknown confounders affecting the micro-
biota composition.
For the microbiota analysis, the 88 children were categorized into 6 treatment groups based
on their antibiotic purchases during the 7-month intervention (Table 1): Control (no antibiotic
or probiotic treatments), Pen (penicillin use during the intervention), Mac (macrolide use dur-
ing the intervention, some also used penicillins), LGG (L. rhamnosus GG group), Pen+LGG (L.
rhamnosus GG + penicillin), and Mac+LGG (L. rhamnosus GG + macrolide). The use of
Fig 1. Flow-chart of the study cohort.
doi:10.1371/journal.pone.0154012.g001
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sulfonamide-trimethoprim (N = 7) and cephalosporins (N = 4) were so uncommon during the
intervention that their association with the microbiota could not be assessed.
Processing of the faecal samples
The faecal samples were collected at home and transported immediately to the study centre for
storage in -70°C, or were initially stored in the home freezer for 0.5–78 hours (on average 19
hours) before being transported to the study center. DNA was extracted from the faecal sam-
ples with the Promega Genomic Wizard DNA Purification Kit (Promega, Madison, WI, USA),
using a modified protocol developed for bacterial DNA extraction from faecal samples [38].
Compliance with the probiotic/placebo treatment was confirmed by testing the post-interven-
tion samples with a qPCR specific for the L. rhamnosus GG strain [38]. Only compliant cases
were included in microbiota analysis. The bacterial composition of the participants’microbiota
was studied using a phylogenetic microarray, the Human Intestinal Track Chip (HITChip),
which is specifically designed for the analysis of the human intestinal microbiota [39]. The
Table 1. Characteristics of the study cohort (N = 231). Control = received neither antibiotics nor L. rhamnosusGG during the intervention; Pen = received
penicillin; Mac = received macrolide and/or penicillin; LGG = received L. rhamnosusGG but no antibiotics; Pen+LGG = received L. rhamnosusGG and peni-
cillin; Mac+LGG = received L. rhamnosusGG and macrolide and/or penicillin.
Control Pen Mac LGG Pen+LGG Mac+LGG Microbiota analysed Microbiota not analysed
N 18 5 9 34 13 9 88 143
Age (months) 66.3 39.4 48.9 67 57.5 68.9 62.2 52.3
Duration of breastfeeding (months) 8.1 6.9 8 8.5 7.8 8.7 8.2 9.1
Weight (kg) 21.4 14.9 15.7 20.1 17.1 21.9 19.4 18.5
Height (cm) 110.3 92.4 96.5 109.4 102.8 114.1 106.8 105
Lifetime antibiotic courses / year 1.2 2.7 3 1.6 1.5 2.3 1.8 1.8
Cases with asthma 0 0 1 0 1 0 2 7
Cases with allergies 3 1 2 5 1 0 12 10
doi:10.1371/journal.pone.0154012.t001
Table 2. Antibiotic use before, during, and after the intervention in the LGG group (N = 124) and placebo group (N = 107).
All antibiotics Macrolide Penicillin Cephalo-sporins Sulfonamide-
trimethoprim
LGG Placebo LGG Placebo LGG Placebo LGG Placebo LGG Placebo
Number of children receiving at least one course
Before 120 102 80 68 112 99 51 50 51 57
During 49 48 14 20 39 35 6 8 6* 15
1yr after 72 69 19 26 57 52 20 21 13* 23
2yr after 84 84 26* 37 65 65 32 28 18 27
3yr after 90 86 30 38 70 65 37 31 20 29
Average number of courses per child
Before 7.4 7.5 1.6 2.0 4.0 3.4 0.8 0.9 1.0 1.1
During 0.7 1.0 0.1 0.3 0.5 0.5 0.1 0.1 0.1* 0.2
1yr after 1.6 2.1 0.2* 0.4 1.0 1.0 0.2 0.3 0.2 0.4
2yr after 2.5 3.2 0.3* 0.7 1.4 1.5 0.4 0.5 0.3 0.6
3yr after 2.8 3.5 0.4* 0.8 1.6 1.5 0.5 0.6 0.4 0.6
Signiﬁcant differences between the LGG and the placebo groups are indicated by * and bold font. The signiﬁcance is based on χ2-test (antibiotic use
frequencies) and t-test (average number of courses).
doi:10.1371/journal.pone.0154012.t002
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microarray consists of oligonucleotide probes targeting the hyper-variable regions V1 and V6
of the 16S rRNA gene, allowing the identification and relative quantification of not only previ-
ously cultured and named, but also uncultured bacterial phylotypes. Microarray analysis of the
bacterial DNA was performed essentially as described previously [39]. The signal intensities of
the oligonucleotide probes were translated into abundances of 1038 species-level phylotypes,
130 genus-like taxa, and 23 higher level taxa (9 phyla; Firmicutes divided down to Clostridium
clusters and Bacilli) using the fRPA pre-processing algorithm [40]. The genus-like taxonomy is
formed by grouping together related (>90% similarity of 16S rRNA gene sequence) organisms,
which is the established cut-off for 16S-based genus annotation, and which has been shown to
correlate well with FISH (fluorescence in situ hybridization) -based quantitation of bacterial
genera [39]. The groups are named according to the nearest cultured relative. The microbiota
data were transformed into relative abundances by dividing the signal intensities of each taxon
by the total intensity of the sample. The microarray data are available in S2 Table.
Statistical analyses
To investigate the associations between L. rhamnosus GG treatment and antibiotic purchases
(as a proxy for bacterial infections) from the beginning of the intervention in 2009 until the
end of 2012 we included 231 children (placebo group, N = 107; L. rhamnosus GG group,
N = 124). Survival analysis (with survival regression models, assuming the exponential distri-
bution) was conducted to test if the treatment groups differed in their persistence without anti-
biotics. The end outcome in the models was the first antibiotic purchase. Negative binomial
models were used to analyse the cumulative number of courses purchased by different time
points.
The number of gastrointestinal (GI) complaints before, during and after antibiotic courses
was analysed in a sub-cohort including 96 cases that had purchased antibiotics during the
intervention (placebo group, N = 47; L. rhamnosus GG group N = 49). Using a paired-sample
Wilcoxon-test, we tested whether the frequency of GI complaints (average number of com-
plaints/day) was higher after an antibiotic course than before in the groups Pen, Mac, Pen
+LGG, and Mac+LGG. Using the Kruskal-Wallis test, we tested whether the difference in the
GI complaint frequency before and after an antibiotic course was different between the Pen
and Pen+LGG groups, and between the Mac and Mac+LGG groups.
Species diversities were calculated for each faecal sample as the inverse Simpson index of
the species-level data. Microbiota stability was calculated as the Pearson correlation between
the pre- and post-intervention sample. The principal coordinates analysis was conducted with
the log-transformed species-level data, using Pearson correlation distances. The influence of
the probiotic and antibiotic treatments on the genus-level microbiota was analysed with nega-
tive binomial models, controlling for the baseline microbiota composition, and thereby any fac-
tor that may have influenced the baseline composition such as age, health, and antibiotic use
history, by including the baseline abundance of the focal bacterial group in the model. Thus
further stratification was not necessary. The timing of the antibiotic course during the interven-
tion had no impact on the estimated effect of the antibiotic, and was therefore excluded from
the analysis. Due to the large number of genus-level bacterial groups (130), only the false dis-
covery rate—corrected p-values<0.05 were considered as significant and were reported. The
genus-level bacterial groups significantly associated with the treatments were clustered based
on their response profiles (estimated effects of the treatments from the negative binomial mod-
els) to visualize, which bacterial groups respond to the treatments similarly.
All statistical analyses were conducted with the program R [41], using the packages vegan
[42], MASS [43], nlme [44], and survival [45].
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Results
L. rhamnosusGG supplementation caused a reduction in antibiotic use
Using the Finnish drug purchase registry, we were able to accurately follow the antibiotic use of
the study children during and for nearly 3 years after the intervention. The treatment groups
did not differ in prior antibiotic use or prevalence of asthma or allergies (Tables 1 and 2).
The prevalence of total antibiotic use during the intervention did not significantly differ
between the treatment groups (Fig 2, Table 2). During the intervention, 44% of the placebo
group and 40% of the L. rhamnosus GG group received antibiotics. However, the prevalence of
sulfonamide-trimethoprim use was significantly reduced in the L. rhamnosus GG group (rela-
tive risk, RR = 0.34, 95% confidence interval 0.14–0.85, Fig 2, Table 2). During the follow-up
period after the intervention, the difference in antibiotic use between the groups gradually
increased (Fig 2). There was a significant difference in the proportion of children treated with
macrolides (RR = 0.68, 95% CI = 0.46–1.02) and sulfonamide-trimethoprim (RR = 0.6, 95%
CI = 0.36–0.99) by the end of the follow-up period (Fig 2). The difference in penicillin and
cephalosporin use was smaller and not significant.
The number of antibiotic courses purchased per child followed similar patterns (Fig 3): the
cumulative number of antibiotic courses was consistently lower in the L. rhamnosus GG group,
and the difference was especially clear in macrolide and sulfonamide-trimethoprim courses.
The L. rhamnosus GG group received 49% fewer macrolide and 72% fewer sulfonamide-tri-
methoprim courses per person during the intervention. By the end of the follow-up, the L.
rhamnosus GG group had received 48% fewer macrolide and 36% fewer sulfonamide-trimetho-
prim courses per person.
Fig 2. Incidence of antibiotic use (%) in the placebo and L. rhamnosusGG groups. The dashed line shows the end of the intervention. The p-values
indicate the significance of the difference (indicated by the arrows at different time points, based on survival regression models) in antibiotic use between the
groups at the end of the intervention, 1 year after the intervention, 2 years after the intervention, and 2.7 years after the intervention.
doi:10.1371/journal.pone.0154012.g002
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L. rhamnosusGG protected against macrolide-associated
gastrointestinal disturbance
There frequency of gastrointestinal complaints in the children that received antibiotics during
the intervention (number of complaints per day per child) was on average highest during the
week before the start of an antibiotic course (Fig 4), with no differences between the L. rhamno-
sus GG and placebo group (p = 0.96). There was a borderline significant increase in the fre-
quency of complaints during the week before a course compared to the previous month in the
placebo group (p = 0.04) and in the L. rhamnosus GG group (p = 0.11). Neither penicillin nor
macrolide courses were associated with an immediate increase in the frequency of symptoms
during the course in either treatment group. However, during the month after a macrolide
course, there was a significantly higher frequency of complaints in the placebo group as com-
pared to the probiotic group (p = 0.03).
L. rhamnosusGG intake modified the children’s faecal microbiota
In the children that were not treated with antibiotics, the L. rhamnosus GG treatment caused
microbial changes (S1 Table), although the diversity and stability were unaffected (Fig 5).
According to permutational multiavariate analysis of variance, the treatment explained 4% of
the inter-individual variation in the species-level microbiota composition (p = 0.001) among
the non-antibiotic-treated children. The abundance of relatives of Lactococcus, Lactobacillus
gasseri, Ruminococcus lactaris, uncultured Mollicutes, Prevotella melaninogenica and P. oralis
were significantly elevated in the probiotic group, while the abundance of relatives of Eubacte-
rium cylindroides, Clostridium ramosum, and Escherichia coli were reduced (S1 Table).
Fig 3. Cumulative number of antibiotic courses per person in the placebo and L. rhamnosusGG groups. The dashed line shows the end of the
intervention. The p-values indicate the significance of the difference (indicated by the arrows at different time points, based on negative binomial models) in
antibiotic use between the groups at the end of the intervention, 1 year after the intervention, 2 years after the intervention, and 2.7 years after the
intervention.
doi:10.1371/journal.pone.0154012.g003
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L. rhamnosusGG did not protect from macrolide-associated changes in
the microbiota
Antibiotic use was strongly associated with the post-intervention microbiota composition,
explaining 14% of the inter-individual variation in both the placebo and probiotic groups (per-
mutational multivariate analysis of variance, p = 0.001). In both groups, the microbiota of the
macrolide-treated children deviated most strongly from the non-antibiotic treated children.
Macrolide use was associated with reduced diversity and stability of the microbiota (Fig 5). The
effect of penicillins on the microbiota was limited and the microbiota of the penicillin users
resembled the microbiota of the non-antibiotic-users (S1 Table, Figs 5 and 6).
Most of the macrolide users, regardless of probiotic use, had a distinct microbiota composi-
tion with low diversity (Fig 5), and a high abundance of Bacteroides spp. (Fig 7). To see which
bacterial groups responded similarly to the treatments, the bacterial groups significantly associ-
ated with either antibiotic or L. rhamnosus GG treatment were clustered into 10 groups based
on their response profiles (Fig 7). A diverse group of taxa belonging to Bacteroidetes, Bacilli,
and Proteobacteria clustered together (Fig 7, grey). Their total abundance was positively associ-
ated with macrolide use. Similarly, the abundance of several Bacteroides groups, together with
Veillonella (Fig 7, light green), as well as the abundance ofHaemophilus, Clostridium ramosum,
andWeissella (Fig 7, violet) was positively associated with macrolide use. Conversely, the abun-
dance of the Actinobacterial genera Bifidobacterium and Collinsella, was negatively associated
Fig 4. Frequency of gastrointestinal complaints per day per person during the intervention. The
frequency of complaints was calculated separately for the following periods: during the month before any
antibiotic course, during the week before any antibiotic course, during a penicillin or a macrolide course, and
during the month after a penicillin or a macrolide course. Some children received several courses and
therefore contributed to the calculation of penicillin and macrolide-associated symptoms. Significant
differences based on non-parametric Kruskal-Wallis (when comparing groups) and paired-sample Wilcoxon
(when comparing different time periods in the same individuals) -tests are shown.
doi:10.1371/journal.pone.0154012.g004
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with macrolide use, especially in the L. rhamnosus GG group (Fig 7, red). However, the L.
rhamnosus GG treatment appeared to prevent the penicillin-associated increase of Clostridium
cluster I (the genus-level group Clostridium sensu stricto), and the relatives of Clostridium diffi-
cile, uncultured Mollicutes, andHaemophilus spp. (S1 Table, Fig 6).
Discussion
The influence of long-term L. rhamnosus GG supplementation on antibiotic use, antibiotic-
associated gastrointestinal complaints, and on the intestinal microbiota was investigated in 2–7
Fig 5. Microbiota diversity and stability by treatment group.Diversity after the intervention was calculated as the Inverse Simpson index (panel A), and
microbiota stability as the Pearson correlation between the pre- and post-intervention sample (panel B). Significant differences based on analysis of variance
are shown.
doi:10.1371/journal.pone.0154012.g005
Fig 6. Microbiota composition by treatment group.Composition in the placebo group (panel A) and L. rhamnosusGG group (panel B). The component
scores were calculated using principal coordinates analysis of the Pearson correlation distances in the species-level data. All samples were included in the
same analysis, and the groups are shown in different panels for clarity.
doi:10.1371/journal.pone.0154012.g006
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year old children. Contrary to earlier observations in short interventions with adults [31,32],
the consumption of L. rhamnosus GG changed the microbiota composition of the children.
Macrolide use was associated with strong changes in the microbiota, which the L. rhamnosus
GG treatment did not prevent completely. However, the intake of L. rhamnosus GG did appear
to prevent some of the penicillin-associated changes in the microbiota. Most intriguingly, the
use macrolide and sulphonamide-trimethoprim antibiotics was significantly reduced in the
intervention group for up to three years post-intervention.
Several genus-level bacterial groups were significantly associated with the treatment, indi-
cating that the regular consumption of L. rhamnosus GG for 7 months has the potential to alter
certain aspects of the intestinal microbiota in children. The observed changes occurred largely
(but not exclusively) among the bacteria residing in the small intestine: species related to Lacto-
coccus and Lactobacillus gasseri increased in abundance by 4.5-fold (p<0.0001) and 1.9-fold
(p = 0.005), respectively, while the relatives of Escherichia coli decreased by 2.5-fold
(p<0.0001). The daily consumption of L. rhamnosus GG is likely to increase the concentration
of its main metabolic product, lactic acid, in the small intestine, which may promote other lac-
tic acid bacteria and conversely reduce the abundance of competing Proteobacteria that are less
acid-tolerant. This may be a beneficial change, as many species and strains related to E. coli are
potentially pathogenic and produce the inflammatory lipopolysaccharide (LPS) [46]. However,
such changes have not been observed in previous studies with adults [31,32], indicating that
the adult microbiota may be more resistant to modulation than the developing microbiota of
preschool children, or that long-term supplementation is necessary for changes in the micro-
biota to occur.
Fig 7. Bacterial groups associated with the treatments.Genus-level bacterial groups significantly
associated with at least one of the treatments (L. rhamnosusGG or antibiotics), clustered based on their
response profile to the L. rhamnosusGG and antibiotics. The average total abundances (± standard error) of
the clusters in the different treatment groups are shown in the barplots. Significance of the difference from the
control group (based on negative binomial models) are indicated by the asterisks: * p<0.05; ** p<0.01; ***
p<0.001.
doi:10.1371/journal.pone.0154012.g007
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Although the L. rhamnosus GG intervention appeared to have some beneficial effects on the
microbiota and was associated with reduced frequency of GI complaints after a macrolide
course, it failed to prevent most of the macrolide-associated changes in the microbiota. This
indicates that the protective effect of L. rhamnosus GG during antibiotic treatment is not
caused by stabilization or a faster recovery of the overall microbiota. Macrolide use in both the
L. rhamnosus GG and the placebo group was associated with a clear and consistent pattern of
low abundance of the Actinobacterial genera Bifidobacterium and Collinsella, and a high abun-
dance of Bacteroides species related to B. fragilis, B. ovatus, B. stercoris, and B. uniformis and
many groups of Proteobacteria. The only clear benefit of the L. rhamnosus GG intervention
was observed on the relatives of Eubacterium hallii, a butyrate-producer [47], which declined
in the placebo-treated macrolide users but not in the L. rhamnosus GG—treated ones. Whether
the protective effect of L. rhamnosus GG on E. hallii or other butyrate producers during macro-
lide treatment is general and results in a reduction of gastrointestinal disturbance remains to be
verified.
Nearly all children using macrolides had increased levels of Bacteroides spp. Many Bacter-
oides species are often macrolide-resistant [48], which may explain their increase. An elevated
abundance of Bacteroides spp. in children has been associated with increased serum IgE levels
[49] and with type I diabetes [50,51]. Species related to B. fragilis and B. ovatus, the two groups
that were strongly increased in the macrolide-users, have been associated with childhood over-
weight [52], aberrant immune function, including diabetes [53,54] and intestinal symptoms
[55,56].
Pencillin use was associated with a weaker shift in the microbiota composition than macro-
lide use. The abundance of Clostridium cluster I, relatives of Clostridium difficile, uncultured
Mollicutes, andHaemophilus spp. were all significantly increased in the placebo-treated peni-
cillin-users. However, these changes did not occur in the probiotic group, indicating that the
probiotic may be effective in protecting the microbiota against penicillin-associated distur-
bance and increase in potential pathogens.
Previously, Lactobacillus-Bifidobacterium supplementation in adults during H. pylori eradi-
cation therapy (amoxicillin-clarithromycin-lansopratzole) and during amoxicillin treatment
has been shown to enable a quicker recovery of the microbiota [35]. Our results show that
long-term L. rhamnosus GG administration may have similar effects in children, enabling a
faster recovery from or increased resilience against penicillin-associated disturbance. However,
the treatment was ineffective against macrolide-associated disturbance, with Bifidobacterium
even more strongly depressed by the macrolide in the L. rhamnosus GG group than in the pla-
cebo group. These results suggest that the combination of Lactobacillus and Bifidobacterium
strains may be more effective in preventing antibiotic-associated changes in the microbiota
than Lactobacillus alone.
Perhaps the most important finding was that the use of macrolide and sulphonamide-tri-
methoprim antibiotics was significantly and persistently reduced after the intervention for up
to 3 years. However, beta-lactam (penicillins and cephalosporins) use was unaffected by the
treatment. This suggests that either a type of infection that is treated with macrolide and sul-
phonamide-trimethoprim, but not with beta-lactam antibiotics, was prevented by the L. rham-
nosus GG treatment, or that beta-lactam purchases are not a good proxy for infections. The
latter would be the case if beta-lactam antibiotics were prescribed more leniently than the other
antibiotic types, even when a bacterial infection has not been verified. The reduction of antibi-
otic use is an encouraging result, in terms of the threat of antibiotic resistance and in terms of
the impact antibiotic exert on the microbiota. L. rhamnosus GG intake may prevent antibiotic-
associated changes in the microbiota and the potential metabolic and immunological conse-
quences indirectly by preventing infections and thus reducing antibiotic use.
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The results confirm that long-term L. rhamnosus GG supplementation has no clear adverse
effects on the microbiota or overall health of 2–7 year old children. It appears to have a benefi-
cial influence on the microbiota composition, to prevent penicillin-associated changes in the
microbiota, and to confer a long-term protection against certain infections.
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